Beximco Grows At Home And Abroad
Company Focused On ‘Expanding Portfolio And Consolidating International Presence’
Bangladeshi generics manufacturer Beximco has reported 12.3% annual sales growth for its 2020 financial year and 9.9% turnover growth for its financial first quarter ending 30 September 2020. The company remains focused on expanding its portfolio and consolidating its international presence.
You may also be interested in...
Bangladesh's Beximco has claimed a world first with the launch of a generic version of remdesivir in its domestic market. Local authorities have granted an emergency use authorization for the COVID-19 treatment amid the coronavirus pandemic.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.